Michael C Cardone

US Patent:

20020102617, Aug 1, 2002

Filed:

Aug 3, 2001

Appl. No.:

09/923243

Inventors:

Gavin MacBeath - Arlington MA, US
Stuart Schreiber - Boston MA, US
Peter Sorger - Cambridge MA, US
Michael Cardone - Boston MA, US
John Newman - Cambridge MA, US

International Classification:

G01N033/53
G01N033/542
C12M001/34

US Classification:

435/007900, 435/287200

Abstract:

Driven by the influx of data from genome sequencing projects, systematic efforts are now underway to construct defined sets of cloned genes for high throughput expression and purification of recombinant proteins. To facilitate the subsequent study of protein function, the present invention provides protein microarrays that are compatible with the demand for extremely low sample volume and the rapid, simultaneous processing of thousands of proteins, and methods of assaying these arrays. The proteins are covalently or non-covalently attached to the surface of a solid support and retain their ability to interact specifically with other proteins, polynucleotides, other biological macromolecules, or small molecules.

US Patent:

20040038428, Feb 26, 2004

Filed:

Apr 1, 2003

Appl. No.:

10/404619

Inventors:

Gavin MacBeath - Arlington MA, US
Stuart Schreiber - Boston MA, US
Peter Sorger - Cambridge MA, US
Michael Cardone - Boston MA, US
John Newman - Cambridge MA, US

International Classification:

G01N033/543

US Classification:

436/518000

Abstract:

Driven by the influx of data from genome sequencing projects, systematic efforts are now underway to construct defined sets of cloned genes for high throughput expression and purification of recombinant proteins. To facilitate the subsequent study of protein function, the present invention provides protein microarrays that are compatible with the demand for extremely low sample volume and the rapid, simultaneous processing of thousands of proteins, and methods of assaying these arrays. The proteins are covalently or non-covalently attached to the surface of a solid support and retain their ability to interact specifically with other proteins, polynucleotides, other biological macromolecules, or small molecules.

US Patent:

20160038503, Feb 11, 2016

Filed:

Nov 21, 2013

Appl. No.:

14/646586

Inventors:

David RICHARD - Littleton MA, US
Michael H. CARDONE - Dorchester MA, US

International Classification:

A61K 31/5377
A61K 31/496
A61K 31/573
A61K 31/454
A61K 45/06
A61K 31/69

Abstract:

The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.